Anasuya Dighe, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Education & Training
- PhD
- Indian Institute of Science, Computational Biology
- MSc
- University of Pune, Bioinformatics
- BSc
- University of Pune, Biotechnology
Research
Copy Link
Overview
Medical Research Interests
Biological Evolution; Computational Biology; Exome Sequencing
ORCID
0000-0002-0444-5969
Research at a Glance
Yale Co-Authors
Frequent collaborators of Anasuya Dighe's published research.
Publications Timeline
A big-picture view of Anasuya Dighe's research output by year.
Research Interests
Research topics Anasuya Dighe is interested in exploring.
David A. Braun, MD, PhD
Soki Kashima, MD, PhD
Yansheng Liu, PhD
Gunter Wagner, PhD
Marc Machaalani
Michael Hurwitz, MD, PhD
13Publications
154Citations
Computational Biology
Biological Evolution
Publications
2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
Motzer R, Albiges L, Aguirre S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arija J, Tykodi S, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun D, Powles T, Choueiri T. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Annals Of Oncology 2026, 37: 861-871. PMID: 41720427, DOI: 10.1016/j.annonc.2026.02.011.Peer-Reviewed Original ResearchCitationsAltmetric
2025
24TGF-Beta alters CD8+ T cell phenotype and drives resistance to immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC)
Rout R, Kashima S, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 24TGF-Beta alters CD8+ T cell phenotype and drives resistance to immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.025. PMCID: PMC12509635, DOI: 10.1093/oncolo/oyaf276.025.Peer-Reviewed Original Research31Lymphocyte heat shock signature predicts response to immune checkpoint blockade in renal cell carcinoma
Burns E, Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Atkins M, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 31Lymphocyte heat shock signature predicts response to immune checkpoint blockade in renal cell carcinoma. The Oncologist 2025, 30: oyaf276.032. PMCID: PMC12509613, DOI: 10.1093/oncolo/oyaf276.032.Peer-Reviewed Original Research41Single-cell dissection of immunosuppressive myeloid subclusters driving resistance to immune checkpoint therapy in renal cell carcinoma (RCC)
Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 41Single-cell dissection of immunosuppressive myeloid subclusters driving resistance to immune checkpoint therapy in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.042. PMCID: PMC12509592, DOI: 10.1093/oncolo/oyaf276.042.Peer-Reviewed Original ResearchProgressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.Peer-Reviewed Original ResearchCitationsAltmetricSpatial Genomic Approaches to Investigate HOX Genes in Mouse Brain Tissues
Shelar A, Dighe A. Spatial Genomic Approaches to Investigate HOX Genes in Mouse Brain Tissues. Methods In Molecular Biology 2025, 2889: 235-244. PMID: 39745616, DOI: 10.1007/978-1-0716-4322-8_16.Chapters
2023
Experimental and phylogenetic evidence for correlated gene expression evolution in endometrial and skin fibroblasts
Dighe A, Maziarz J, Ibrahim-Hashim A, Gatenby R, Kshitiz, Levchenko A, Wagner G. Experimental and phylogenetic evidence for correlated gene expression evolution in endometrial and skin fibroblasts. IScience 2023, 27: 108593. PMID: 38174318, PMCID: PMC10762354, DOI: 10.1016/j.isci.2023.108593.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Proteotype coevolution and quantitative diversity across 11 mammalian species
Ba Q, Hei Y, Dighe A, Li W, Maziarz J, Pak I, Wang S, Wagner GP, Liu Y. Proteotype coevolution and quantitative diversity across 11 mammalian species. Science Advances 2022, 8: eabn0756. PMID: 36083897, PMCID: PMC9462687, DOI: 10.1126/sciadv.abn0756.Peer-Reviewed Original ResearchCitationsAltmetricTracing the cis-regulatory changes underlying the endometrial control of placental invasion
Suhail Y, Maziarz JD, Novin A, Dighe A, Afzal J, Wagner G, Kshitiz. Tracing the cis-regulatory changes underlying the endometrial control of placental invasion. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2111256119. PMID: 35110402, PMCID: PMC8832988, DOI: 10.1073/pnas.2111256119.Peer-Reviewed Original ResearchCitationsAltmetricEvolution of higher mesenchymal CD44 expression in the human lineage
Ma X, Dighe A, Maziarz J, Neumann E, Erkenbrack E, Hei YY, Liu Y, Suhail Y, Kshitiz, Pak I, Levchenko A, Wagner GP. Evolution of higher mesenchymal CD44 expression in the human lineage. Evolution Medicine And Public Health 2022, 10: 447-462. PMID: 36148042, PMCID: PMC9487634, DOI: 10.1093/emph/eoac036.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link